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Acitre tin h as recentl y been introduced to replace e tre tinate in 
the treatment of severe psoriasis due to a considerable sho rter 
rrnina l h alf-life . The previously recommended 2-month t~ticonceptive period after acitre tin treatment has been ex-
:ended t o 2 ye.ars after the detectio n of etretinate in cert~ in 
ci tre tin recIpIents. In the present study , 10 patIents w Ith 
aever e p sori asis w ere treated with 30 m g acitre tin daily for 3 ~onths . Seven pati ents h ad de tectable mean steady-state 
lasma e tre tinate concentrations in the ran ge o f 2.5 to ~6 . 7 n g /ml. Four of the patients showed te ratoge nic levels of 
las rna e tre tinate. Consumptio n of a lco hol appeared to be an 
P mporta nt contributin g facto r for the formation of etretinate. ~s judged from the dose- and body-weig ht - no rmalized 
AV e v a lues (~UCcor) there :,as a ~rea ~ i.nte r-ind!vid~al varia-
tion (s i x fold) 111 the systemIc avaIl abIlIty o f aCltret1l1. After 
I n 1 972 Boll ag discovered two aromatic retinoids, etretinate and acitretin, which produced a significa nt regression of c h e mically induced papillomas in mice and possessed a good the rapeutic index [1,2] . Etre tinate was selected for clinical tria ls for two reasons: It was found more active 111 mice after 
both o ra l and parenteral administration and secondly showed better 
as t ro intes t111al absorption (also \11 mice) [3]. 
g Etre tinate was found to be of major success in the treatment of 
variou s disorders of keratinization such as severe psorias is vul garis 
[4] and pustular and eryth rodermic psorias is [5,6]. Unfortunately, it 
reveale d a profound pharmacokinetic disadvantage of being slowly 
elimina t e d after chronic dosing [7 - 9] due to accumulation in adi-
pose tissu e [10 ,11]. In contrast, acitretin has been shown not to 
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Abbrev iations: 
A V e: calculated area under the plasma concentration curve corre-
sponding to a dose interval at steady-state (which equals AUC 
from zero time to infiniry after a single dose) 
e l: plasma drug clearance 
em : maximum drug concentration in plas ma 
e,,: m ean steady-state concentration calculated as AUCT/T , where 
A V CT is the area under the concentration curve at a dose in terval (T) 
HPLe: hi gh-performance liquid chromatography 
t' /2ka: half-time of the first-order absorption phase 
t
'
/ 2- 0' : distributive half-time of disposition 
t
'
/2-P: terminal half-li fe of drug disposition 
tm: time to maximum drug concentration 
discontinuation o f therapy, the rate o f eliminatio n of both 
acitretin (t1/ 2 ran ge 1.0 to 25 .4 d) and 13-cis-acitre tin (tl /2 
ran ge 1.5 to 25.7 d) w as found to be related to the observed 
mea r~ steady-state l e~e l o f etretinate as evidenced by a lo n ger 
term1l1al tl /2 o f patIents w Ith hIg h levels of e tretinate in 
plasm a. A m ean terminal elimination half-life of e tre tinate 
w as found to be 45.7 d ± 10.6 (mean ± SD; ran ge 27 .0 to 
59.3 d). The risk of m etabolic fo rm ation of e tre tinate in aci-
t retin recipie~ts m akes it imposs ib le to draw any definite 
conclusl,on Wltl.1 regard to .recommendatio n oflen gth o f anti-
conceptl:re penod foll owll1g acitretin therapy in psoriatics. 
M Ol1ltorll1g o f plasm a et re tinate levels in acitretin- treated 
fertile w o m en is advisable. ] flwest Dermatol 100:623 - 627 
1993 } 
accumulate in adipose tissue [1 2] and is consequently eliminated 
from the body consl.derably fas ter than etretinate [1 3- 15]. 
Etret1l1ate and aCltretll1 are potentiall y teratogenic dru gs [1 6]. 
Due to a comparable cIini.ca l effi cacy of the two compounds [1 7, 18] 
and because women of chtldbeanng potential might be permitted to 
become pregnant sooner after stopping therapy with acitretin than 
those comple.tin g etretinate therapy, th e fonner dru g has recently 
replaced etretl11ate 111 many European countries. H owever, the previ-
ously recommended 2-month anticonceptive period after acitreti n 
therapy has recently been extended to 2 years after some preliminary 
results. 111 both !1l1mans [1 9] and rats [20] demonstrating etretinate in 
aCltretl11 reclplent~ . In ra ts ethanol appears to be a contributing 
factor for the estenficatlon of aCltretl11 to etretinate [20] w hereas no 
;n 11; 110 data are available from humans. ' 
. This is the first pharmaco kinetic study with the aim of dete rmin-
I11 g t.he concentration levels and terminal elimination half-life of 
etretl11ate as a metabolite in psoriatic patients after long-term acitre-
tin therapy. A possible influence of ethanol on the mean steady-state 
etret1l1ate leve l was evaluated by recording patients' alcohol con-
sumption. In addition, plasma concentrations of parent dru g and its 
13-cls metabolIte were also investi gated. 
PATIENTS AN D MET HODS 
Patients The stud y was approved by the local ethics committee 
and ~he N~tlOna l H ealth Serv ice of Denmark according to the Dec-
laratIOn of HelSinki II. A to tal of 10 patients participated in the 
study: three women, ages 36 to 56 years (mean 43 years) and seven 
men, ages 44 to 56 years (mean 51 years) (Tab le I). Eight patients 
had pson aSls vul gan s, and two patients had pa lmoplantar pustular 
pSOrIaSIS (patients 4 and 6). Good hea lth , as evidenced by normal 
phYSical and laboratory tests fo r hematologic, hepatic, and renal 
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Table I. Characteristics of the Patients 
Sex Age Body Weight 
Patient (F/M) (years) (kg) 
I '" M 51 70 
2 F 37 65 
y.' M 51 88 
4' F 36 56 
5' M 47 78 
6 F 56 79 
7',' M 53 90 
8b., M 44 74 
9'·, M 56 58 
10'·, M 56 92 
• More than 20 cigarettes per day. 
b Patients with detectable plasma etretinate levels. 
, Less than 20 cigarettes . 
Ethanol Intake 
(g/week) 
150-200 
< 20 
150-200 
< 20 
150-200 
<20 
150-200 
<20 
450-550 
450-550 
function, was required for in,lusion in the study. Liver biopsy or 
liver scan was not performed. No patients had received systemic 
retinoid medication before. They were free of concomitant medica-
tion except one patient (number 1) receiving nizatidin (150 mg 
twice daily) for gastritis. Combined regimens with ultraviolet B or 
photochemotherapy (psoralens with ultraviolet A) were not al-
lowed. The patients included smokers and nonsmokers of tobacco. 
It was estimated from their histories of drinking habits that patients 
2, 4, 6, and 8 consumed on average less than 20 g of ethanol per 
week . The daily alcohol consumption of patients 1, 3, 5, and 7 was 
estimated to be much higher than that of the previous group, mainly 
in the form of beer (range of150 to 200 g ethanol weekly) (Table I). 
Patients 9 and 10 had abstained from consumption of alcohol for a 
longer period prior to the study but initiated an excessive alcohol 
consumption shortly after initiation of the study and continued so 
during the time of plasma sampling. They consumed on average 
more than 70 g of ethanol daily, mainly in the form of beer. None of 
the patients ingested the capsules together with alcohol. 
Females of childbearing potential used an effective form of con-
traception 2 months before the trial and for at least 2 years following 
cessation of therapy. To monitor patient compliance, remaining 
acitretin capsules were counted each month. 
Treatment and Blood Sampling Capsules containing 10 mg 
of acitretin in spray-dried powder were supplied by Hoffmann-La 
Roch e & Co. AG, Basel, Switzerland. Each subject was treated with 
acitretin for a period of 3 months. The daily dose was administered 
as three 10-mg capsules ingested together with breakfast. Venous 
blood 10 ml was taken for blank determinations before the investi-
gation. During the initial and the final 4-week period predose data 
were obtained. At cessation of therapy after 3 months, an indwelling 
intravenous catheter was inserted in an ante-cubital vein to collect 
blood samples, the first prior to dosing and the others taken after 
one-half, 1, 1 and one-half, 2, 4, 6, 8, 12, 24, 28, 36, and 48 h. 
Following the 48-h sample, blood samples were obtained by individ-
ual venipuncture at 3, 5, 7, 9, 15, 21, 28, 35, 56, and 64 dafter 
stopping therapy . 
Specimen Collection and Analysis Because of the sensitivity 
of retinoids to light, all samples were immediately processed under 
minimal li ght, and after centrifugation the plasma samples were 
stored at -70· C until analyzed. Blood samples were collected into 
vacutainer tubes that contained ammonium oxalate as anticoagu-
lant. 
The concentration of acitretin and 13-cis-acitretin was deter-
mined by a previously published reversed-phase high-performance 
liquid chromatography (HPLC) method with slight modification 
[21]. Ascorbic acid, sodium edetate, ammonium acetate (plasma 
pH = 6) and internal standard (isotretinoin 200 ng) were added to 
1.0-ml plasma samples and extracted with 6 ml of diethyl ether. 
After evaporation of the organic phase to dryness with nitrogen at 
40 · C and redissolving in 100)11 methanol, 50)11 was injected onto 
the HPLC system. The HPLC system consisted of a Shimadzu 
LC-6A pump (Kyoto, Japan), a Spark-Holland Promis automatic 
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injector (Emmen, Netherlands), a Hitachi Variable UV detector 
(Tokyo, Japan) set at 365 nm, and a Shimadzu C-R3A integrating 
recorder. To improve the separation of the chromatographic peaks 
of the cis- and trans-isomers the chromatographic eluent was 
changed from 80% acetonitrile, pH 7, to 75% acetonitrile, pH 4. 
This change resulted in changes in retention volumes of acitretin 
and 13-cis acitretin from 5.75 to 7.5 ml and from 5.25 to 6.5 mI, 
respectively. Standard curves in the working range 5 -100 ng/ml 
were constructed from at least five known samples. When concen-
trations were expected to be higher than 100 ng/ml plasma samples 
were diluted to within the working range with proved drug-free 
blank plasma before analysis. The minimum detectable concentra-
tion [within analysis coefficient of variation (CV) less than 25%] 
was estimated to be 5 ng/ml for both acitretin and the 13-cis metab-
olite (following Hoffmann-La Roche AG, Basel guidelines for 
"Good Laboratory Practice") . Quality control samples in the low, 
medium, and high concentration ranges were analyzed with each 
series of unknown samples . Plasma samples were run in duplicate. 
A new method for determination of etretinate was developed 
because the chromatographic performance under the conditions 
mentioned above was insufficient. A shorter column (12 em) with 
NucleosiI300-5.£L C18 and an eluent consisting of 82% acetonitrile 
in 0.1 M ammonium acetate, pH 7, with a flow rate of 1.8 mljmin 
sharpened the chromatographic peak and lowered the retention 
time to 4.1 min (retention volume 7.4 ml) whereas peaks for acitre-
tin and 13-cis acitretin eluted with the solvent front. The internal 
standard was changed from isotretinoin to the isopropyl ester of 
acitretin, a compound with chemical properties much like those of 
etretinate. The internal standard was completely separated from 
etretinate and had a retention time of 5.8 min. Minimum detectable 
level was 2 ng/ml (CV < 25%) and standard curves were linear in 
the range 2-75 ng/ml using 0.5 ml plasma samples. No interfering 
compounds from plasma were observed at any time . 
Pharmacokinetic Analysis Curve fitting to the observed multi-
ple-dose concentration/time data for acitretin was performed by 
means of non-linear, iterative regression analysis using the com-
puter-program Kinon-85,2 (Nielsen-Kudsk) [22] . The model func-
tion for the fitting used was Cp = A' e-at + B' e-Pt + C' e-I<>" where 
Cp is the plasma drug concentration; A', B', and C' are multiple-
dose concentration coefficients; and a, p, and k. are apparent dispo-
sition and absorption rate constants, respectively. The maximum 
plasma concentration (Cm ) and the time at which this occurred (tJ 
was determined from the individual plasma concentration profiles. 
Derived parameters (phasic half-lives, single-dose coefficients A, B, 
e) were determined according to the principles previously de-
scribed [9]. The trapezoidal method was used to calculate the area 
under the steady-state plasma concentrations curves corresponding 
to the last dose interval. The determined individual areas were nor-
malized by division with the dose of the drug per kilogram body 
weight (AU Ceo, values) . Terminal elimination rate constants for 
acitretin and its metabolites were obtained from plasma concentra-
tion-time data determined during a period of up to 64 d after cessa-
tion of drug administration. The derived apparent first-order rate 
constants k. and a should be considered as hybrid constants that do 
not uniquely describe the absorption and distribution processes in 
the organism. Mean steady-state concentrations were calculated as 
C" (mean) = AUCT/T, where AUCT is the area under the concen-
tration curve at a dose interval (T) at steady state. Statistical signifi-
cance of differences between determined parameters was evaluated 
using the two-tailed t-test for paired groups. p < 0.05 was consid-
ered statistically significant. 
RESULTS 
The plasma concentration profiles of acitretin and its metabolites 
13-cis-acitretin and etretinate after the last oral dose given 3 months 
after initiation of treatment are shown for patient 9 (Fig 1). After 
stopping of therapy for 3 months the disappearance rates of the drug 
and its metabolites in plasma were followed for 64 d although trun-
cated in the figure at28 d. 
All pre-treatment plasma samples were found to contain no etre-
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. re 1. Time course of plasma concentrations for 24 h at steady state for 
Fl.~etin and its metabolites 13-cis-acitretin and etretinate in patient 9 (top) . 
~~e daily oral dose of acitretin was 30 mg. The bottom fi gure shows the 
concen tra tion courses (truncated at 28 d) of drug and metabolttes from 
J rna after cessation of therapy. The fi gures represent the computer-gencr-
P d curves of best fit obtained by iterative non-linear regress ion analysis of 
:~~ plotted acitrctin data. The concentration-time data for etretinate and 
13_cis-acitretin showed l.rregular varJ~tlons and could not be analyzed ph~r­
rnacokinetically. Acltretm concentratIon are shown as closed sqll~ res, 13-cls-
acit[etin concentrations as ope/l sq lla res, and etretinate concentrations as open 
circles. 
. teo Etretinate was detectable (2: 2 ng/ ml) after discontinuance of [lna . . C I 4 d . . 3 C 
acitretin administration II1patJent 1 ror at east 6 , ~n patlent lor 
56 d, in p atient 5 for 34 d, m patient 7 for 28 d, 111 patient 8 for 57 d, 
and in p atients 9 and 10 p.resumably. for more t~l an 28 and 43 d, 
respectively. A mean termmal half-bfe for etretmate of 45.7 d ± 
10.6 (mean ± SD; range 27.0 to 59 .? d) was observed. The concen-
tration-time data obta111ed m a dose 111terval after 3 months of treat-
ment showed irregul ar variations and could not be analyzed 
pharmacokinetically. All plasma samples from patients 2, 4, and 6 
were free of etretinate. The possible presence of impurities of etre-
rinate in acitretin capsules were ruled out by analysis of capsules 
returned by the patients. No detectable levels of etretinate were 
observed when acitretin calibration samples were analyzed. Further-
more, control acitretin-containing samples kept under conditions 
identical to patients' samples did not show any traces of etretinate, 
and replicate analysis of the clinical trial samples connrmed the 
presence or absence of etretinate. 
The concentration-time data course for the parent drug acitretin 
could in all cases be fitted to a three-exponential pharmacokinetic 
function, with one parameter representing oral absorption and two 
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other terms representing distributive and terminal disposition. The 
maximum plasma concentration occurred within about 1.4 to 4.1 h 
(tm ) , whereas the apparent absorption half-lives (t1/ 2k.) ranged from 
0 .72 to 2.88 h and the a-phase (tl12a) from 1.44 to 6. 18 h. After 
therapy was stopped, the terminal half-lives of the parent drug 
varied between 1.02 and 25.4 d (mean 8.02 ± 8.26 SD) and for the 
metabolite 13-cis-acitretin between 1.48 and 25.7 d (mean 7.7 ± 
8.1 SO) . Following correction of the individual AUC values by 
dividing by the respective subjects dose per kg body weight, the 
calculated harmonic mean AUC values (AUCcor) for aci trerin and 
13-cis-acitretin were similar and of the order of 4354 ng' h/ ml ± 
.2815 (mean ± SD) and 4720 ng· h/ml ± 2446 (mean ± SD), re-
spectively. Asjudged from the AUCcor-values, it also appears that a 
considerable interindividual variation exists with regard to the sys-
temic availability of the parent dru g (Table II). 
Virtually all of our patients developed xerosis, cheilitis, and dry-
ness of mucous membranes, but no severe side effects were observed 
during the course of treatment. A definite correlation between sever-
ity of adverse effects and determined pharmacokinetic parameters 
for both parent drug and metabolite(s) could not be demonstrated. 
Any influence of tobacco smoking on pharmacokinetic parameters 
was not found. 
DISCUSSION 
The aim of the present study was to evaluate the pharmacokinetics 
of etretinate as a metabolite of acitretin during chronic treatment of 
patients with severe recalcitrant psoriasis. The influence of ethanol 
on the conversion of acitretin to etretinate was evaluated by record-
ing patients' alcohol consumption. The results obtained showed 
measurable leve.ls of etretinate in seven of ten acitretin-treated pa-
tients. The findmgs confirm some preliminary results from a Euro-
pean Multicenter Trial in which 59 patients were treated with a 
daily oral. dose of 10 to 50 mg acitretin for at least 2 months [23]. Of 
these patients, 12 had etretinate concentrations higher than 5 ng/ 
ml , 24 showed etretl11ate traces, and 23 had no detectable ecretinate 
concentrations. 
In etretinate-treated patients, the parent drug is rapidly hydro-
lyzed to the corresponding acid (acitretin) or its 13-cis isomer in the 
i?itial biotransformation step [7) (Fig 2). Until recently this hydroly-
SIS was conSidered non-reversible. The subsequent metabolic path-
way is .ap~arently a demethylation of the methoxy group at the 
~romatl~ nng and subsequently elimination as the beta-glucoronide 
111 the bile of those metabolites with intact side-chain , or by renal 
excretIOn of those metabolites .with shortened side-chain [14,24). 
Fourteel~ metabolites ~haractenzed by a shortening of the tetraene 
slde~cha111 were Identified by H anni et III (25) in the urine of two 
pson atlc patients receiving an oral 100-mg dose of 10, 11-3H side-
chal11 labeled etretinate. At present the role of metabolites for the 
pharmacologic effects of acitretin and etretinate is unknown. 
. In a st~dy by L6fberg et al [26] etretinate was administered by 
111tragastnc 1l1fuslon throughout organogenesis in the mouse (day 
8-15). Mean etretinate concentrations of 6.5 ng/ml in maternal 
plasma resulted in retinoid-specific defects, in particular shortening 
of hmbs and cleft palate. In the present study, four of ten patients 
showed teratogenic levels of plasma etretinate and two patients had 
levels just below (4.4 and 5.9 ng/ml) . 
The study was not designed to determine the mechanism of the 
etretinate formation, but a possible mechanism can be suggested. 
C hou et II I [20] have found that simultaneous administration to rats 
of a single dose of acitretin, with varying amounts of ethanol, 
showed a dose-dependent formation of etreti nate. Furthermore, in 
vitro studies in both rat and human liver supernatants have demon-
strated that ethanol enhances but does not seem to be essentia l for 
the formation of etretinate. The esterification was shown to involve 
enzymatic catalysis. Miller and DeLuca [27) showed that all-trallS-
retinolc acid (which has a reactive side-chain similar to that of 
acitretin) is metabolized to ethyl retinoate in rat liver microsomes 
and that the reaction is greatly stimulated by the addition of acetyl 
coenzyme A (CoA) , suggesting the formation of a retinoic acid-
CoA intermediate (retinoyl-CoA). Ethanol metabolism includes 
formation of acetate and may increase the concentration of CoA. 
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Table II. Pharmacokinetics of Acitretin and Its Metabolites 13-cis-Acitretin and Etretinate Determined After Steady-State 
Discontinuance of Oral Administration of 30 mg Acitretin Daily for 3 Months 
Acitretin 
Dose tm Cm t162k. t(l2fr t(c2P AUC<o, 
Patient (mg/kg) (h) (ng/ml) h) h) d) (ng' h/ml) 
1 0.43 1.9 200 1.20 1.44 5.26 2,512 
2 0.46 1.9 343 1.44 1.68 1.02 4,544 
3 0.34 1.4 194 1.90 2.16 3.41 3,473 
4 0.54 4.1 268 2.16 2.40 8.53 3,138 
5 0.39 3.1 366 1.92 1.97 5.93 6,929 
6 0.38 4.1 149 2.16 2.40 4.22 3,771 
7 0.33 4.0 192 2.08 2.16 1.99 4,458 
8 0.41 4. 1 187 2.80 2.82 3.76 4,847 
9 0.52 1.9 208 0.72 6.1 8 25.4 3,720 
10 0.33 4.1 291 2.88 3.60 20.7 12,153 
Mean 0.41 3.1 240 1.93 2.68 8.02 4,354 
±SD 0.07 1.1 69 0.67 1.37 8.26 2,815 , 
Thus, if a low concentration of CoA is rate-limiting in the forma-
tion of etretinate from acitretin, ethanol metabolism could increase 
the velocity by enhancing CoA formation . A simil ar mechanism of 
ethanol-induced increase in acety lation is known to take place with 
other drugs (i .e., sulphadimidine) [28]. In accordance with the 
above-mentioned facts, the relatively high AUCco, levels of etretin-
ate after 3 months of acitretin treatment observed in two of our 
patients could be related to their alcohol consumption. 
Although not a primary objective of our study, the multiple dose 
pharmacokinetic parameters for acitretin and its 13-cis isomer were 
also estimated . For acitretin we evaluated AUCco< and C lo,,1 (deter-
mined as the reciprocal of AUCco<) because these parameters reflect 
absorption, first-pass effect, and elimination [29]. Mean AUC,o, 
(and Clo"l) values in the present study were comparable with those 
reported previously also in psoriatic patients [9,15]. Compared to 
the other patients and also to previous results [9,1 5] a prolonged 
terminal elimination phase for both acitretin (tl/.Jl = 25.4 and 
20.7 d) and 13-cis acitretin (tl/.Jl = 21.1 and 25.7 d) was observed 
in the two patients with high levels of etretinate (patients 9 and 10). 
The metabolism and subsequent elimination of acitretin and 13-cis 
ac itretin as metabolites of etretinate appears to be limited by the 
formation rate [14]. Consequently, the rate of elimination of the 
metabolites is dependent on the elimination rate of parent drug 
(etreti nate). 
In summary, we detected etretinate in seven of 10 psoriatic pa-
tients receiving chronic acitretin therapy. Four of the patients 
showed mean steady-state plasma etretinate concentrations exceed-
ing a teratogenic level of 6.5 ng/ml. Concomitant intake of alcohol 
appears to be an important contributing factor for the conversion. A 
mean terminal half- life for etreti nate of 45.7 d ± 10.6 (mean ± 
SO; range 27.0 to 59.3 d) was observed, which is somewhat less 
than previously found [8,9] . The clinical implications are important 
because of the teratogenic potentials of oral retinoids. After long-
term acitretin therapy the recommended period for using anticon-
Etretinate 
Acltretin 13-cis-Acitretin 
Figure 2. Proposed ill villo metabolism of ctretinate, acitrctin, and 13-cis-
acitretin. 
13-cis-Aci tretin Etretinate 
Mean Mean Mean 
C" AUC<o, t(c2P C" AUC,o, t(c2P C" (ng/ml) (ng' h/ml) d) (ng/ml) ng ' h/ml) d) (ng/ml) 
45.0 1,909 3.85 34.2 385 54.2 6.9 
87 .1 3,897 1.48 74.7 0 0 
49 .2 2,788 1.71 39.5 311 45.9 4.4 
70.6 5,289 6.60 119.0 0 0 
112.6 6,566 6.24 106.7 628 43.9 10.2 
59.7 4,920 3.20 77.9 0 0 
61.3 3,338 2.88 45.9 429 27.0 5.9 
82.8 4,332 3.97 74.0 146 39.4 2.5 
80.6 3,171 21.1 68.7 2,617 59.3 56.7 
167.1 10,989 25.7 151.1 3,702 50.2 50.9 
81.6 4,720 7.7 79 .2 45.7 
34.2 2,446 8.1 35.2 10.6 
ceptive measures is at least 2 years. Metabolic formation of etretinate 
in acitretin recipients and storage in adipose tissue of etretinate (t l/2 
up to about 120 d or more) makes it impossible to draw any definite 
conclusion about the exact period during which pregnancy should 
be avoided. When a fertile woman who has been previously exposed 
to acitretin desires to attem~t concep.tion, measurement of plasma 
etret1l1ate level may provide I11fOrmatlOn about the teratogenic risk. 
However, if acitretin therapy is undertaken, fertile women should 
be informed of potential teratogenicity. 
Pari of this stlldy \Vas supported by Hqfflllall-La Roche & Co. 
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